KPTI News & Events

Karyopharm will present the results of its Phase 3 SENTRY trial in a presentation at the 2026 ASCO Annual Meeting. The SENTRY results were also published this morning in the peer-reviewed Journal of Clinical Oncology. Selinexor in combination with ruxolitinib demonstrated a rapid and near doubling of patients achieving spleen volume reduction of 35%, or SVR35 at Week 24, versus ruxolitinib, with a consistent SVR35 benefit observed across prespecified subgroups. Reductions in symptoms were consistent across each domain. Overall survival signal with greater than 50% reduction of risk of death versus ruxolitinib. More patients achieved greater than or equal to 20% reductions in VAF as early as week 24 vs. ruxolitinib. The combination demonstrated a manageable safety and tolerability profile consistent with the known profile of selinexor and ruxolitinib individually. No new safety signals were observed. The percentage of patients treated with the combination who experienced TEAEs leading to death occurred in 0.9% of patients receiving the combination compared to 2.6% of patients receiving ruxolitinib alone.

Reports Q1 revenue $35.1M, consensus $31.4M. "As we move through 2026, Karyopharm is in a pivotal period with meaningful clinical and regulatory milestones ahead," said CEO Richard Paulson. "Through Q2 and Q3 of 2026, we expect several important developments that have the potential to create significant value for the company, while improving outcomes for patients. In endometrial cancer, we have completed enrollment in our Phase 3 XPORT-EC-042 trial and remain on track to report topline data in mid-2026. In myelofibrosis, the Phase 3 SENTRY results reinforced the potential of selinexor to meaningfully improve patient outcomes, including a statistically significant SVR35 benefit and a promising overall survival signal. With the endometrial cancer readout ahead and the myelofibrosis regulatory and guideline path coming into focus, we believe these programs could meaningfully expand the impact and long-term opportunity of the selinexor franchise."

Karyopharm sees 2026 revenue $130M-$150M, consensus $137.49M